Clinical Trial Update: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating golimumab (MK-8259) utilization and impact in ulcerative colitis with completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ulcerative Colitis | Phase 4 | Status: COMPLETED | Results posted: 2017-10-13